Treatment with oral beta‐blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction
Authors:
- 9 January 2014
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 121 (5) , 618-626
Abstract
Objective: To investigate the effect on fetal growth of treatment with oral beta‐blockers during pregnancy in women with congenital or acquired heart disease.Design: Historical matched cohort study.Setting: Centre for Pregnant Women with Heart Disease, Copenhagen University Hospital, Denmark.Population: A cohort of 175 women with heart disease, grouped according to beta‐blocker treatment, and a cohort of 627 women from the overall population matched on seven birthweight‐determining factors.Methods: Differences between groups were tested by simple descriptive statistics and assessed using standard hypothesis tests. Associations were estimated by correlational analysis and multivariable regression.Main outcome measure: Proportion of infants born small for gestational age (SGA).Results: More of the infants exposed to beta‐blockers were SGA compared with non‐exposed infants (29.4 versus 15.3%; P < 0.05). After adjustment for birthweight‐determining factors, beta‐blocker treatment and maternal body mass index (BMI) were the only factors independently associated with SGA (the relative difference in expected birthweight was −8.6%; 95% CI −13.3 to −3.9%; P = 0.0004). After adjustment for BMI, beta‐blocker treatment was associated with an increased risk of SGA (OR 2.65; 95% CI 1.15–6.10; P = 0.02). In a subgroup with isolated tachyarrhythmias, SGA infants were more frequent in the beta‐blocker exposed group compared with the non‐exposed group (31 versus 10%; P < 0.005). Beta‐blocker treatment was the only independent predictor of SGA, adjusting for several factors influencing fetal growth (the relative difference in expected birthweight was −12.2%; 95% CI −19.9 to −3.9%; P = 0.001).Conclusions: In a historical cohort of pregnancies complicated by maternal heart disease, treatment with beta‐blockers was found to be independently associated with an increased risk of delivering an SGA infant.Keywords
This publication has 27 references indexed in Scilit:
- β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort studyBMJ Open, 2012
- ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)European Heart Journal, 2011
- How to manage hypertension in pregnancy effectivelyBritish Journal of Clinical Pharmacology, 2011
- Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta‐blockers during pregnancyPharmacoepidemiology and Drug Safety, 2010
- Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small‐for‐gestational‐age newbornsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2010
- Chronic kidney disease in pregnancyBMJ, 2008
- Antihypertensive drug therapy for mild to moderate hypertension during pregnancy2007
- Recurrence Rates of Arrhythmias During Pregnancy in Women With Previous Tachyarrhythmia and Impact on Fetal and Neonatal OutcomesThe American Journal of Cardiology, 2006
- Oral beta-blockers for mild to moderate hypertension during pregnancyCochrane Database of Systematic Reviews, 2003
- The effect of valvular heart disease on maternal and fetal outcome of pregnancyJACC, 2001